PT88329A - Bacterias nao virulentas contra infeccoes estreptococicas - Google Patents

Bacterias nao virulentas contra infeccoes estreptococicas

Info

Publication number
PT88329A
PT88329A PT88329A PT8832988A PT88329A PT 88329 A PT88329 A PT 88329A PT 88329 A PT88329 A PT 88329A PT 8832988 A PT8832988 A PT 8832988A PT 88329 A PT88329 A PT 88329A
Authority
PT
Portugal
Prior art keywords
streptococcal infections
bacteria
virulent bacteria
bacteria against
against streptococcal
Prior art date
Application number
PT88329A
Other languages
English (en)
Other versions
PT88329B (pt
Original Assignee
Edwuin H Beachey
Thomas H Beachey
Michael A Kehoe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edwuin H Beachey, Thomas H Beachey, Michael A Kehoe filed Critical Edwuin H Beachey
Publication of PT88329A publication Critical patent/PT88329A/pt
Publication of PT88329B publication Critical patent/PT88329B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/879Salmonella
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/885Streptococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT88329A 1987-08-24 1988-08-24 Bacterias nao virulentas contra infeccoes estreptococicas PT88329B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/088,626 US5162226A (en) 1987-08-24 1987-08-24 Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products

Publications (2)

Publication Number Publication Date
PT88329A true PT88329A (pt) 1989-06-30
PT88329B PT88329B (pt) 1995-07-03

Family

ID=22212456

Family Applications (1)

Application Number Title Priority Date Filing Date
PT88329A PT88329B (pt) 1987-08-24 1988-08-24 Bacterias nao virulentas contra infeccoes estreptococicas

Country Status (12)

Country Link
US (1) US5162226A (pt)
EP (1) EP0305279B1 (pt)
JP (1) JPH02420A (pt)
AT (1) ATE120487T1 (pt)
AU (1) AU631524B2 (pt)
CA (1) CA1341255C (pt)
DE (1) DE3853454T2 (pt)
DK (1) DK472988A (pt)
FI (1) FI97603C (pt)
HU (1) HU205263B (pt)
NO (1) NO174630C (pt)
PT (1) PT88329B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
US5846547A (en) * 1996-01-22 1998-12-08 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6355255B1 (en) * 1998-12-07 2002-03-12 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
US6399097B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corporation Composition for treatment of a bacterial infection of the digestive tract
US6406692B1 (en) 1997-10-31 2002-06-18 New Horizons Diagnostics Corp Composition for treatment of an ocular bacterial infection
US6428784B1 (en) * 1997-10-31 2002-08-06 New Horizons Diagnostics Corp Vaginal suppository for treating group B Streptococcus infection
US6399098B1 (en) 1997-10-31 2002-06-04 New Horizons Diagnostics Corp Composition for treating dental caries caused by streptococcus mutans
US20020136712A1 (en) * 1997-10-31 2002-09-26 Fischetti Vincent Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae
US7232576B2 (en) 1997-10-31 2007-06-19 New Horizons Diagnostics Corp Throat lozenge for the treatment of Streptococcus Group A
US20030082110A1 (en) * 1997-10-31 2003-05-01 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6432444B1 (en) 1997-10-31 2002-08-13 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymes for treating dermatological infections
US20030129146A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti The use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6277399B1 (en) * 1997-10-31 2001-08-21 New Horizon Diagnostics Corporation Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections
US6056954A (en) 1997-10-31 2000-05-02 New Horizons Diagnostics Corp Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses
US20030129147A1 (en) * 1997-10-31 2003-07-10 Vincent Fischetti Use of bacterial phage associated lysing proteins for treating bacterial dental caries
US6752988B1 (en) * 2000-04-28 2004-06-22 New Horizons Diagnostic Corp Method of treating upper resiratory illnesses
US6423299B1 (en) 1997-10-31 2002-07-23 Vincent Fischetti Composition for treatment of a bacterial infection of an upper respiratory tract
US20020127215A1 (en) * 1999-09-14 2002-09-12 Lawrence Loomis Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections
US7063837B2 (en) * 1999-09-14 2006-06-20 New Horizons Diagnostics Corp Syrup composition containing phage associated lytic enzymes
US7256265B2 (en) * 1999-12-03 2007-08-14 Regents Of The University Of Minnesota Streptococcal C5a peptidase vaccine
AU2001259205A1 (en) * 2000-04-28 2001-11-12 New Horizons Diagnostic Corporation The use of bacterial phage associated lysing enzymes for treating various illnesses
US6395504B1 (en) 2000-09-01 2002-05-28 New Horizons Diagnostics Corp. Use of phage associated lytic enzymes for the rapid detection of bacterial contaminants
CA2427928A1 (en) * 2000-11-02 2002-12-27 New Horizons Diagnostics Corporation The use of bacterial phage associated lytic enzymes to prevent food poisoning
US20040213765A1 (en) * 2001-07-13 2004-10-28 Vincent Fischetti Use of bacterial phage associated lytic enzymes to prevent food poisoning
AU2002365223A1 (en) * 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US7255867B2 (en) * 2002-11-15 2007-08-14 Id Biomedical Corporation Of Quebec Vaccine
CN102203122A (zh) 2008-11-05 2011-09-28 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
JP2015522692A (ja) 2012-07-16 2015-08-06 ファイザー・インク 糖およびその使用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480779B2 (fr) 1979-08-30 1986-07-18 Anvar Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
US4735801A (en) * 1982-09-07 1988-04-05 Board Of Trustees Of Leland Stanford Jr. University Novel non-reverting salmonella live vaccines
US4550081A (en) * 1980-05-19 1985-10-29 The Board Of Trustees Of The Leland Stanford Jr. University Non-reverting salmonella
US4284537A (en) 1980-07-03 1981-08-18 The United States Of America As Represented By The Department Of Health And Human Services Conjugate of streptococcal M protein peptide vaccine
US4666847A (en) 1981-01-16 1987-05-19 Collaborative Research, Inc. Recombinant DNA means and method
WO1982003088A1 (en) * 1981-03-09 1982-09-16 Corp Cetus Vaccines
US4625252A (en) 1981-09-03 1986-11-25 Basf Aktiengesellschaft Guide system and magnetic tape cassette comprising such a system
US4597967A (en) * 1982-07-27 1986-07-01 The University Of Tennessee Research Corp. Synthetic polypeptide fragments
US4521334A (en) 1982-07-27 1985-06-04 The University Of Tennesse Research Corporation Synthetic polypeptide fragments
US4454121A (en) * 1982-07-27 1984-06-12 The University Of Tennessee Research Corporation Synthetic peptides corresponding to antigenic determinants of the M protein of Streptococcus pyogenes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4919930A (en) * 1983-06-10 1990-04-24 University Of Tennessee Research Corporation Synthetic M proteins-streptococci type 5
US4784948A (en) * 1983-08-10 1988-11-15 The Rockefeller University Production of streptococcal m protein immunogens and molecular probes
WO1985003521A1 (en) * 1984-02-01 1985-08-15 Enterovax Research Pty. Ltd. Bacterial strains
US4666846A (en) 1984-02-17 1987-05-19 Eli Lilly And Company Novel cloning vectors containing selectable genetic markers for use in streptomyces and related organisms

Also Published As

Publication number Publication date
DE3853454D1 (de) 1995-05-04
AU2145188A (en) 1989-03-09
EP0305279B1 (en) 1995-03-29
FI883876A (fi) 1989-02-25
FI97603C (fi) 1997-01-27
DE3853454T2 (de) 1995-11-09
ATE120487T1 (de) 1995-04-15
AU631524B2 (en) 1992-12-03
HUT50048A (en) 1989-12-28
NO174630C (no) 1994-06-08
NO174630B (no) 1994-02-28
NO883763D0 (no) 1988-08-23
DK472988A (da) 1989-02-25
DK472988D0 (da) 1988-08-24
NO883763L (no) 1989-02-27
FI883876A0 (fi) 1988-08-22
EP0305279A1 (en) 1989-03-01
PT88329B (pt) 1995-07-03
CA1341255C (en) 2001-06-19
JPH02420A (ja) 1990-01-05
HU205263B (en) 1992-04-28
FI97603B (fi) 1996-10-15
US5162226A (en) 1992-11-10

Similar Documents

Publication Publication Date Title
PT88329A (pt) Bacterias nao virulentas contra infeccoes estreptococicas
ES2097115T3 (es) Procedimiento para la integracion de un gen elegido en el cromosoma de una bacteria y bacteria obtenida por dicho procedimiento.
NZ512574A (en) Novel streptococcus antigens useful as vaccines
BR0208944A (pt) quadros de leitura aberta de streptococus pneumoniae codificando os antìgenos de polipeptìdeos e seus usos
HUP0102304A1 (hu) B Csoportba tartozó Streptococcus antigének
AU2001276619A1 (en) Immunisation against chlamydia pneumoniae
HUP0002475A2 (hu) Módosított immunogén pneumolizinkészítmények mint vakcinák
ATE332376T1 (de) Bakterielle ausscheidungsproteine und darauf beruhende azelluläre impfstoffe
SE8601325L (sv) Sett att producera ett immunglobulinbindande protein samt medel for detta
PT672116E (pt) Mutantes por supressao como vacinas contra a colera
ATE41034T1 (de) Herstellung von protein a.
SE8502162L (sv) Framstellning av protein g och/eller fragment derav
ES2137310T3 (es) Vacuna contra una infeccion por streptococcus suis.
Argaman et al. Polyribitol-phosphate: an antigen of four gram-positive bacteria cross-reactive with the capsular polysaccharide of haemophilus influenzae type B
AR029622A1 (es) Una bacteria pasteurellaceae gram-negativa que comprende una mutacion en un gen, una composicion inmunogenica, una composicion de vacuna, un metodo para producir una mutante de dicha bacteria, un metodo para producir dicha bacteria atenuada, un polinucleotido purificado y aislado de la misma, un vec
AU548623B2 (en) Production of antibodies
DE68916424D1 (de) Pasteurella-impfstoff.
DK125887A (da) Beskyttelse af heste mod streptococcus equi
IE810618L (en) Pasteurella vaccines
FI971402A (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi
DE69532524D1 (de) Sekretorischer rekombinanter bcg impfstoff gegen aids
FR2330409A1 (fr) Procede de preparation d'un nouveau vaccin antileptospirose monovalent, et vaccin ainsi obtenu
KR850700110A (ko) 백신 및 이의 제조방법
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20020731

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20020731